Neisseria meningitidis oligosaccharide conjugated to corynebacterium diphtheriae CRM197
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2010
- First approval year
- 2010
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Neisseria meningitidis oligosaccharide conjugated to corynebacterium diphtheriae CRM197
- menveo
- Menveo
- Licensed GSK MenACWY vaccine (Menveo)
- licensed gsk menacwy vaccine menveo
- MenACWY (Menveo) vaccine
- MenACWY-CRM (Menveo)
- Menveo
- Menveo®
- Menveo® (meningitis ACWY vaccine)
- neisseria meningitidis oligosaccharide conjugated to corynebacterium diphtheriae crm197
- Neisseria meningitidis oligosaccharide conjugated to corynebacterium diphtheriae crm197
- ChEMBL ID
- CHEMBL6068368
- First in class
- No
- Orphan designation
- No
Mechanisms of action
- Mechanism
- Oligosaccharide conjugated to Corynebacterium ciphtheriae CRM197 vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Oligosaccharide conjugated to Corynebacterium ciphtheriae CRM197
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Meningitis, Meningococcal
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001040
- Subject identifier
- D008585
- Condition identifier
- EFO_0004249
- Condition identifier
- EFO_1001040
- Condition identifier
- MONDO_0005373
- Highest recorded phase
- 4
- Event
- asthenia
- Reports
- 9
- Reporting signal score
- 15.8142
- Event
- eosinophilia
- Reports
- 5
- Reporting signal score
- 17.78
- Event
- extensive swelling of vaccinated limb
- Reports
- 1
- Reporting signal score
- 8.92355
- Event
- factor vii deficiency
- Reports
- 1
- Reporting signal score
- 7.77853
- Event
- generalised oedema
- Reports
- 5
- Reporting signal score
- 21.0958
- Event
- hyperpyrexia
- Reports
- 7
- Reporting signal score
- 38.621
- Event
- loss of consciousness
- Reports
- 4
- Reporting signal score
- 7.10606
- Event
- pyrexia
- Reports
- 10
- Reporting signal score
- 17.2796
- Event
- rash
- Reports
- 6
- Reporting signal score
- 6.5989
- Event
- rash erythematous
- Reports
- 6
- Reporting signal score
- 20.1013
- Event
- vaccination site erythema
- Reports
- 2
- Reporting signal score
- 15.5856
- Event
- vaccination site inflammation
- Reports
- 1
- Reporting signal score
- 8.30456
- Event
- vaccination site pain
- Reports
- 2
- Reporting signal score
- 15.33
- Event
- vaccination site pruritus
- Reports
- 1
- Reporting signal score
- 8.5669
- Event
- vaccination site rash
- Reports
- 1
- Reporting signal score
- 9.26001
- Event
- vaccination site reaction
- Reports
- 1
- Reporting signal score
- 8.4716
- Event
- vaccination site swelling
- Reports
- 1
- Reporting signal score
- 7.50232
- Event
- wrong product administered
- Reports
- 2
- Reporting signal score
- 9.04741
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (52)
- A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
- A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
- A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
- A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays
- A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants
- A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M
- A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
- A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults
- A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY
- A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
- A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age
- A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.
- A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.
- Adolescent MenACWY Booster Study
- B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
- Comparison of Two Meningococcal ACWY Conjugate Vaccines
- Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women
- Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women